Drugs / CB CAR-NK182
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06464965 | Jul 2024 → Oct 2025 | gastric cancer, pancreatic adenocarcinoma | Zhejiang Provincial People's Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB CAR-NK182 | “cord blood-derived CAR-NK cells (CB CAR-NK182) targeting Claudin18.2” NCT06464965 ↗ |
| Modality | Cell therapy | “cord blood-derived CAR-NK cells” NCT06464965 ↗ |
| Route | Intravenous | “Administered via intravenous infusion” NCT06464965 ↗ |